(Q33391825)

English

Phase 2 trial of concurrent 5‐fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity‐modulated radiation therapy for locally advanced head and neck cancer

scientific article published on September 9, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase 2 trial of concurrent 5‐fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity‐modulated radiation therapy for locally advanced head and neck cancer (English)

1 reference

10.1002/CNCR.25374

https://api.crossref.org/works/10.1002/CNCR.25374

10 July 2024

phase II clinical trial

0 references

adaptive radiation therapy

0 references

1 reference

based on heuristic

inferred from title

head and neck cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

advanced head and neck cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

head and neck carcinoma

1 reference

based on heuristic

inferred from title

author name string

Johnny Kao

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vishal Gupta

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael Rivera

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vivek Gurudutt

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Marita Teng

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Eric M. Genden

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830768

10 July 2024

Edelweiss L. Policarpio

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830768

10 July 2024

Ryan J. Burri

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830768

10 July 2024

Peter M. Som

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830768

10 July 2024

Stuart H. Packer

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830768

10 July 2024

language of work or name

0 references

publication date

9 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.25374

1 reference

10.1002/CNCR.25374

https://api.crossref.org/works/10.1002/CNCR.25374

10 July 2024

https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.25374

1 reference

10.1002/CNCR.25374

https://api.crossref.org/works/10.1002/CNCR.25374

10 July 2024

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

318-326

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

21 January 2018

Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent advances in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoradiotherapy for locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of positron emission tomography standard uptake value and pathologic specimen size in cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

HPV-induced oropharyngeal cancer, immune response and response to therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25374

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group [...]

25

1 reference

10.1002/CNCR.25374

https://api.crossref.org/works/10.1002/CNCR.25374

10 July 2024

Identifiers

10.1002/CNCR.25374

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33391825&oldid=2200283368"